Badger Meter Inc vs Merck & Co., Inc. — how do they compare? Badger Meter Inc trades at $134.68 (market cap $3.93B), while Merck & Co., Inc. trades at $133.87 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 81.9× Badger Meter Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.61%). Which is the better fit depends on your goals.
| BMI | MRK | |
|---|---|---|
Market Cap | $3.93B | $321.77B |
Sector | Technology | Health |
52-Week High | $193.09 | $131.84 |
52-Week Low | $113.41 | $77.60 |
Enterprise Value | $3.84B | $368.53B |
Dividend Yield | 1.18% | 2.61% |
Signals from Pluang's Aura AI — not financial advice
Badger Meter (BMI) trades at $133.63, down 2.06% amid bearish technical signals and mixed earnings performance. The stock shows strong profitability with 14.27% net margin and 18.48% ROE, but faces headwinds from recent securities class action lawsuits and declining revenue projections for 2026. Technical indicators suggest bearish momentum with resistance at $137-$139 levels.
While BMI maintains solid fundamentals and analyst consensus targets $155.20 (16% upside), near-term risks include legal uncertainties and earnings volatility. The company's water technology focus provides defensive characteristics, but investors should weigh class action litigation risks against the stock's valuation premium (P/E 31.78).
MRK trades at $133.6, up 2.06% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average support. Recent earnings have consistently beaten estimates, with Q3 2026 expected at $2.27 EPS. The company's acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while revenue growth remains steady at $65.01B in 2025.
MRK presents a positive outlook with a consensus price target of $140.36, indicating potential upside. Strong institutional buying and a 67.57% buy rating from analysts support bullish sentiment. Risks include rising debt-to-asset ratios and competitive pressures in the pharma sector. The dividend yield of $0.85 per half-year adds income appeal for long-term investors.
Trailing returns across standard periods
Latest headlines on both assets
Badger Meter provides industry-leading water management solutions. Its smart measurement hardware and software analytics help water utilities and industrial customers optimize operations and conserve natural resources.
Read more on BMI →Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →